Mani, Laila-Yasmin; Vogt, Bruno; Burnier, Michel; Golshayan, Déla (2011). [Rationale and clinical evidence for the use of rituximab in glomerular diseases]. Revue médicale suisse, 7(290), pp. 819-824. Médecine & Hygiène
Full text not available from this repository. (Request a copy)Autoimmune glomerulopathies are an important cause of chronic kidney disease. Conventional treatments based on steroids, antiproliferative and cytotoxic agents are efficacious, but highly toxic. Because of their central role in the pathogenesis of autoimmunity, B cells have become an attractive therapeutic target. Rituximab is a monoclonal antibody directed against CD20 expressed on the surface of B cells, inducing profound depletion of B cells in the peripheral blood. In spite of encouraging results regarding the off-label use of Rituximab in membranous nephropathy, systemic lupus erythematosus and small vessel vasculitis, controlled, long-term data, and data with specific renal endpoints are currently lacking.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension |
UniBE Contributor: |
Mani, Laila-Yasmin, Vogt, Bruno |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0025-6749 |
Publisher: |
Médecine & Hygiène |
Language: |
French |
Submitter: |
Laila-Yasmin Mani |
Date Deposited: |
16 Mar 2021 08:57 |
Last Modified: |
05 Dec 2022 15:48 |
PubMed ID: |
21595313 |
URI: |
https://boris.unibe.ch/id/eprint/153112 |
Actions (login required)
 |
Edit item |